coronaviru
caus
sever
acut
respiratori
syndrom
sarscov
rel
new
human
pathogen
vaccin
urgent
requir
viru
reemerg
new
outbreak
occur
sarscov
genom
encod
four
structur
protein
spike
membran
envelop
e
nucleocapsid
n
protein
protein
major
surfac
antigen
viru
antibodi
respons
primarili
direct
protein
preclin
studi
sarscov
vaccin
provid
evid
gener
strong
neutral
antibodi
respons
sarscov
may
protect
sar
infect
mani
method
detect
measur
antibodi
respons
sarscov
develop
includ
ifa
elisa
ict
western
blot
viru
neutral
bermingham
et
al
wu
et
al
neutral
assay
allow
sensit
detect
function
antibodi
respons
direct
surfac
protein
envelop
mani
virus
highcontain
virus
like
sarscov
influenza
howev
assay
wide
applic
due
requir
high
biosafeti
laboratori
facil
special
train
personnel
order
effect
address
contain
issu
retrovir
pseudotyp
use
altern
live
viru
pseudotyp
carri
retrovir
rna
genom
code
marker
gene
gfp
luciferas
betagalactosidas
frequent
use
rna
genom
packag
retrovir
core
protein
viral
core
bear
foreign
often
nonretrovir
envelop
protein
surfac
pseudotyp
infect
ie
transfer
genom
contain
transfermark
gene
target
cell
depend
function
foreign
envelop
protein
result
integr
subsequ
express
marker
gene
function
foreign
envelop
therefor
detectedquantifi
measur
marker
gene
express
use
retrovir
particl
pseudotyp
envelop
highcontain
virus
surrog
virus
use
neutral
assay
highli
advantag
use
pseudotyp
approach
envelop
protein
highcontain
viru
requir
possibl
recombin
viru
escap
pseudotyp
undergo
abort
replic
unabl
give
rise
replicationcompet
progeni
temperton
wright
safeti
consider
asid
viru
neutral
assay
pseudotyp
excel
serolog
reagent
encod
report
gene
bear
heterolog
viral
envelop
protein
interest
transfer
report
gene
target
cell
depend
function
viral
envelop
protein
therefor
titr
neutral
antibodi
envelop
measur
reduct
report
gene
transfer
assay
also
readili
adapt
highthroughput
format
use
vaccin
evalu
antivir
screeningresist
assay
monoclon
antibodi
screen
larg
serosurveil
studi
sar
pseudotyp
routin
construct
use
threeplasmid
transfect
approach
fig
construct
retrovir
pseudotyp
achiev
concurr
introduct
sar
spike
envelop
gene
core
retrovir
gene
markerreport
gene
produc
cell
normal
hek
cell
transfect
effici
although
cell
line
may
use
plasmid
sar
spike
envelop
gene
construct
sar
spike
envelop
sequenc
either
nativ
codonoptim
readili
clone
appropri
express
plasmid
permit
incorpor
matur
pseudotyp
express
plasmid
success
use
purpos
includ
pcagg
simmon
et
al
temperton
et
al
nie
et
al
zhang
et
al
phcmv
girogl
et
al
han
et
al
moor
et
al
plasmid
retrovir
construct
two
gene
encod
structur
protein
eg
matrix
nucleocapsid
express
gag
compris
core
enzymat
protein
revers
transcriptas
proteas
integras
express
pol
respons
process
structur
protein
ensur
integr
dsdna
copi
markerreport
gene
addit
lentivir
construct
rev
gene
includ
effici
process
plasmid
markerreport
gene
construct
gene
stabli
integr
targetassay
cell
dna
express
via
singl
plasmid
packag
signal
engin
upstream
gene
ensur
effici
incorpor
fulllength
rna
copi
gene
pseudotyp
capsid
integr
gene
express
via
variou
cisact
transcript
element
note
markerreport
gene
construct
requir
pseudotyp
product
matur
particl
produc
twoplasmid
transfect
construct
sar
spike
envelop
construct
also
pseudotyp
lack
sar
spike
envelop
bud
noninfecti
altern
use
threeplasmid
transfect
system
produc
sar
pseudotyp
necessari
gene
transfect
via
either
one
two
plasmid
use
three
plasmid
detail
howev
offer
greatest
eas
flexibl
switch
plasmid
minim
clone
requir
safeti
less
chanc
recombin
envelop
core
report
gene
express
differ
plasmid
flexibl
system
enabl
tailor
construct
sar
pseudotyp
depend
experiment
requir
transfect
pseudotyp
viru
harvest
store
requir
neutral
assay
fig
neutral
assay
use
sar
pseudotyp
perform
routin
follow
patient
serum
sampl
heatinactiv
min
serial
dilut
appropri
cultur
medium
mix
sar
pseudotyp
viru
volumevolum
ratio
flatbottom
tissu
cultur
plate
clear
plastic
gfp
white
plastic
luciferas
incub
h
approxim
target
cell
ad
well
gfp
luciferas
posit
cell
count
h
later
neutral
antibodi
titer
calcul
temperton
et
al
similar
pseudotypebas
entri
assay
influenza
evalu
tissu
cultur
plate
highthroughput
screen
applic
wang
et
al
order
achiev
maximum
sensit
serolog
assay
vaccin
evalu
seropreval
studi
select
viru
isol
sar
outbreak
use
antigen
equival
strain
requir
optim
antigen
match
pseudotyp
virus
bear
sarscov
envelop
mani
differ
strain
construct
use
surrog
virus
cell
entri
neutral
assay
hofmann
et
al
construct
hiv
pseudotyp
use
frankfurt
strain
protein
hofmann
et
al
nie
et
al
construct
hiv
pseudotyp
use
synthet
codonoptim
protein
frankfurt
strain
sarscov
order
screen
sera
patient
sar
nie
et
al
four
pseudotyp
normal
use
elisa
assay
assay
perform
use
human
hepatoma
cell
endogen
express
high
level
receptor
han
et
al
construct
mlv
pseudotyp
use
urbani
strain
protein
develop
safe
neutral
assay
sarscov
han
et
al
temperton
et
al
construct
mlv
hiv
pseudotyp
use
urbani
strain
protein
order
profil
neutral
antibodi
respons
glycoprotein
sequenti
serum
sampl
collect
recov
patient
temperton
et
al
assay
perform
quail
cell
stabli
overexpress
receptor
strain
sar
use
girogl
et
al
construct
mlv
pseudotyp
girogl
et
al
zhang
et
al
construct
hiv
pseudotyp
use
strain
protein
studi
neutral
antibodi
respons
sarscov
infect
patient
assay
cell
line
transduc
sarscov
receptor
use
zhu
et
al
use
hiv
pseudotyp
bear
protein
urbani
strain
sarscov
studi
vitro
neutral
activ
human
monoclon
antibodi
zhu
et
al
thu
date
least
ten
differ
sarscov
spike
glycoprotein
incorpor
success
retrovir
pseudotyp
employ
multitud
cell
tropism
antibodi
assay
spike
protein
coronavirus
also
effici
incorpor
pseudotyp
retrovir
pseudotyp
use
studi
receptormedi
entri
felin
coronaviru
fcov
dye
et
al
human
coronavirus
hofmann
et
al
power
system
like
therefor
pancoronaviru
applic
virolog
immunolog
studi
sarscov
reemerg
result
new
human
outbreak
would
straightforward
updat
neutral
assay
measur
respons
newli
emerg
antigen
variant
upon
avail
viral
rnacdna
sequenc
inform
newli
emerg
sar
viru
public
nucleotid
sequenc
databas
nation
center
biotechnolog
inform
databas
held
http
wwwncbinlmnihgov
spike
gene
pcramplifi
synthes
retrovir
pseudotyp
prepar
use
downstream
neutral
assay
cost
whole
gene
synthesi
decreas
year
year
viabl
proposit
develop
serolog
assay
access
wildtyp
viru
often
sever
limit
small
group
laboratori
cdc
hpa
etc
newli
develop
assay
use
address
crossclad
neutral
potenti
candid
human
vaccin
immunotherapeut
monoclon
antibodi
etc
also
use
evalu
anti
viru
entri
inhibitor
could
readili
adapt
serosurveil
studi
new
outbreak
locat
measur
neutral
antibodi
respons
antigen
divers
sarscov
strain
necessari
accur
titr
pseudotyp
virus
viru
input
dose
may
normal
gfpbase
pseudotyp
readili
titr
use
flow
cytometri
fac
luciferas
pseudotyp
luminometri
pseudotyp
colour
reaction
titr
obtain
method
highli
depend
cell
type
chosen
assay
receptor
densiti
may
differ
wide
cell
type
mani
cell
line
shown
suscept
sarscov
hattermann
et
al
kay
cell
line
previous
employ
predict
suitabl
target
cell
use
pseudotyp
assay
bgm
buffalo
green
monkey
kidney
epithelium
co
monkey
kidney
fibroblast
african
green
monkey
kidney
fibroblast
frhk
rhesu
monkey
fetal
kidney
rhesu
monkey
kidney
epithelium
african
green
monkey
kidney
epithelium
mek
monkey
embryon
kidney
vero
african
green
monkey
kidney
epithelium
vero
clone
vero
human
fetal
kidney
human
liver
hepatocellular
carcinoma
human
liver
hepatocellular
carconoma
human
liver
rabbit
kidney
epithelium
poek
porcin
fetal
kidney
ps
porcin
kidney
method
titrat
standard
retrovir
pseudotyp
rtpcr
determin
viru
particl
number
elisa
determin
gag
level
hiv
mlv
gag
retroviru
core
measur
surfac
envelop
sarscov
spike
content
surfac
content
may
measur
elisa
recent
shown
influenza
pseudotyp
su
et
al
order
pseudotypebas
assay
wide
applic
within
differ
laboratori
avail
differ
report
system
highli
desir
fig
hiv
gfp
report
modul
pcsgw
describ
recent
use
viral
neutral
assay
temperton
et
al
wright
et
al
modifi
pcr
subclon
express
altern
report
firefli
luciferas
temperton
et
al
wright
et
al
renilla
luciferas
capecchi
et
al
three
assay
type
base
luciferas
report
simplest
use
term
oper
time
data
evalu
howev
due
high
cost
necessari
reagent
luciferas
assay
kit
necess
special
equip
luminomet
assay
may
limit
applic
laboratori
resourcepoor
region
gfp
fluoresc
proteinbas
assay
rfp
yfp
requir
addit
assay
reagent
necessit
avail
special
equip
fluoresc
microscop
interchang
colour
filter
plate
flow
cytometryfac
facil
assay
costeffect
requir
assay
reagent
readili
avail
low
cost
special
equip
unnecessari
express
quantifi
count
infect
cell
use
microscop
follow
stain
xgal
howev
two
colorimetr
substrat
onpg
cprg
chlorophenol
allow
assay
evalu
use
micropl
reader
altern
autom
procedur
use
elispot
reader
count
xgal
stain
blue
cell
may
use
han
et
al
final
avail
multipl
report
use
assay
also
lend
develop
multiplex
assay
would
facilit
measur
neutral
antibodi
respons
surfac
glycoprotein
envelop
deriv
two
differ
viru
famili
eg
sarscov
serosurveil
wet
market
suitabl
sarscov
pseudotyp
neutral
assay
establish
studi
readili
perform
compar
new
surrog
assay
convent
live
viru
neutral
assay
paramet
immun
respons
sarscov
infect
nie
et
al
compar
titr
neutral
antibodi
serum
sampl
analyz
pseudoviru
live
sarscov
neutral
assay
found
strong
correl
two
nie
et
al
temperton
et
al
show
correl
data
neutral
antibodi
titr
measur
plaqu
reduct
assay
versu
titr
measur
pseudotyp
assay
inhibit
viru
entri
endpoint
correl
coeffici
live
viru
versu
pseudoviru
inhibit
respect
temperton
et
al
zhang
et
al
studi
tempor
chang
n
proteinspecif
quantit
elisa
glycoproteinspecif
neutral
antibodi
respons
sarscov
pseudotyp
assay
infect
patient
either
recov
succumb
sarscov
infect
zhang
et
al
good
correl
strong
antibodi
respons
n
protein
diseas
outcom
infect
individu
shown
larg
comprehens
studi
sar
convalesc
patient
sera
strong
tcell
respons
shown
correl
significantli
p
higher
neutral
antibodi
titer
measur
mlv
sar
assay
li
et
al
conclus
sar
pseudotyp
enabl
much
work
current
need
perform
categori
iiiiv
laboratori
undertaken
pseudotyp
categori
ii
environ
repres
highli
flexibl
sensit
system
evalu
neutral
antibodi
spike
surfac
glycoprotein
given
research
council
uk
health
protect
agenc
hpa
current
invit
consult
uk
nation
need
invest
high
contain
laboratori
emphas
applic
pseudotyp
highli
pathogen
envelop
virus
sar
influenza
rabi
west
nile
high
contain
virus
help
extent
allevi
pressur
expens
contain
facil
